RISPERDAL CONSTA 25 MG Israel - English - Ministry of Health

risperdal consta 25 mg

j-c health care ltd - risperidone - powder for suspension for injection - risperidone 25 mg/vial - risperidone - risperidone - risperdal consta is indicated for the treatment of schizophrenia and schizoaffective disorders.risperdal consta is indicated as monotherapy for the maintenance treatment of bipolar i disorder to delay occurrence of mood episodes.risperdal consta is indicated for adjunctive maintenance treatment to delay occurrence of mood episodes in patients with frequently relapsing bipolar disorder.

RISPERDAL CONSTA 37.5 MG Israel - English - Ministry of Health

risperdal consta 37.5 mg

j-c health care ltd - risperidone - powder for suspension for injection - risperidone 37.5 mg/vial - risperidone - risperidone - risperdal consta is indicated for the treatment of schizophrenia and schizoaffective disorders.risperdal consta is indicated as monotherapy for the maintenance treatment of bipolar i disorder to delay occurrence of mood episodes.risperdal consta is indicated for adjunctive maintenance treatment to delay occurrence of mood episodes in patients with frequently relapsing bipolar disorder.

RISPERDAL CONSTA 50 MG Israel - English - Ministry of Health

risperdal consta 50 mg

j-c health care ltd - risperidone - powder for suspension for injection - risperidone 50 mg/vial - risperidone - risperidone - risperdal consta is indicated for the treatment of schizophrenia and schizoaffective disorders.risperdal consta is indicated as monotherapy for the maintenance treatment of bipolar i disorder to delay occurrence of mood episodes.risperdal consta is indicated for adjunctive maintenance treatment to delay occurrence of mood episodes in patients with frequently relapsing bipolar disorder.

RISPOND 1 Israel - English - Ministry of Health

rispond 1

unipharm ltd, israel - risperidone - coated tablets - risperidone 1 mg - risperidone - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episod

RISPOND 2 Israel - English - Ministry of Health

rispond 2

unipharm ltd, israel - risperidone - coated tablets - risperidone 2 mg - risperidone - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episod

RISPOND 3 Israel - English - Ministry of Health

rispond 3

unipharm ltd, israel - risperidone - coated tablets - risperidone 3 mg - risperidone - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episod

RISPOND 4 Israel - English - Ministry of Health

rispond 4

unipharm ltd, israel - risperidone - coated tablets - risperidone 4 mg - risperidone - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episod

RISPOND SOLUTION Israel - English - Ministry of Health

rispond solution

unipharm ltd, israel - risperidone - solution - risperidone 1 mg/ml - risperidone - risperidone - rispond is indicated for the management of schizophrania and manifestation of psychotic disorders. the antipsychotic efficacy of rispond was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. rispond is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. rispond is indicated for the treatment of psychotic manifestations of dementia. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years. rispond is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distract

RISPOND 1 Israel - English - Ministry of Health

rispond 1

unipharm ltd, israel - risperidone - coated tablets - risperidone 1 mg - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

RISPOND 2 Israel - English - Ministry of Health

rispond 2

unipharm ltd, israel - risperidone - coated tablets - risperidone 2 mg - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors